Drug Trial Radar · NCT00509015
Mass-Drug Administration to Reduce Malaria Transmission
Last checked: Nov 19, 2026Latest source record: Aug 13, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6,000
Planned (sponsor's estimate)
Start
Feb 2008
Primary completion
Aug 2008
Study completion Aug 2008
Sponsor
- Lead sponsor
- Radboud University Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Kilimanjaro Christian Medical Centre, Tanzania; London School of Hygiene and Tropical Medicine
- First posted
- Jul 31, 2007
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 1 year
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In the 1950s, the WHO included mass drug administration (MDA) with antimalarial drugs as a tool for malaria control in 'exceptional conditions when conventional control strategies have failed'. Subsequently, MDA has received little attention until the introduction of artemisinin based combination therapy (ACT). The principle aim of MDA is to interrupt malaria transmission by clearing the population of sexual stage parasites, gametocytes, prior to the transmission season. Gametocytes are essential for propagation of the disease and elimination of gametocytes will result in a reduction in malaria transmission. As a consequence, a successful MDA will reduce the burden of disease in a population and is expected to have little influence on the development of protective immunity in areas of low transmission intensity. In Africa, only one large scale MDA study was conducted in the last 10 years. That study, conducted in The Gambia using sulphadoxine-pyrimethamine (SP) plus a single dose of artesunate (AS), failed to show a significant impact of MDA on malaria transmission. Possible reasons for this failure are the limited impact of the drug regimen (a single dose of AS) on malaria transmission, the incomplete coverage, the relatively high transmission intensity in the area and the migration of individuals between villages. Here, we propose to conduct an MDA study in an area of very low malaria transmission intensity in Tanzania. We use the highly active drug combination SP+AS (3 days) followed by a single dose of primaquine..
Conditions
- Malaria, Falciparum
Interventions
Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg)Drug
500mg S\&25mg P/20 kg, 1 day, single dose
Artesunate (day 1,2,3: 4 mg/kg)Drug
4 mg/kg, daily single dose over three days
Primaquine-base (day 3: 0.75 mg/kg)Drug
single dose at 0.75 mg/kg on day 3
placebo tabletsDrug
3 days of lactose tablets (160mg) albochin
Primary outcomes
What the sponsor says the trial is designed to measure.
- malaria morbidity by active and passive case detection.Time frame: during the entire study period
- asexual parasite prevalence and density by microscopy, rapid diagnostic test and molecular QT-NASBATime frame: monthly during the entire study period
- gametocyte prevalence and density by QT-NASBA and microscopyTime frame: monthly during the entire study period
- transmission intensity quantified by entomologic inoculation rateTime frame: continuously during the study period
- human infectious reservoirTime frame: prior to the intervention and several months after the intervention
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Kilimanjaro Christian Medical Centre
Moshi, Tanzania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.